{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PINK1",
        "Protein_Change": {
          "ref": "G",
          "alt": "D",
          "position": "309"
        },
        "variant_string_id": "PINK1 G309D"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in PTEN-induced putative kinase 1 (PINK1) or parkin cause autosomal recessive forms of Parkinson disease (PD), but how these mutations trigger neurodegeneration is poorly understood and the exact functional relationship between PINK1 and parkin remains unclear.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the neurodegeneration in Parkinson's disease caused by mutations in PINK1 and parkin."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses kinase activity assays, co-immunoprecipitation, and in vivo ubiquitination assays to assess the impact of PINK1 mutations on parkin phosphorylation, interaction with other proteins, and ubiquitination activity.",
          "judgment": "Yes",
          "reasoning": "These assays are relevant to understanding the pathogenic mechanism of PD related to PINK1 and Parkin function, which is related to kinase activity, protein-protein interaction, and ubiquitination.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Basic controls, including wild-type and kinase-dead mutants, are included. Multiple replicates are performed:  'Data represent mean ± SEM from three independent experiments.'",
          "judgment": "Yes",
          "reasoning": "The paper uses wild-type and kinase-dead mutants as controls. The data is represented as mean ± SEM from three independent experiments.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic variants were not explicitly used as controls. There is no information about testing variants that reach P/LP criteria *without* relying on PS3/BS3 evidence themselves.",
          "judgment": "No",
          "reasoning": "The paper does not mention the use of known pathogenic variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The data are presented as mean ± SEM and analyzed using ANOVA, with a P-value < 0.05 considered significant. There is no mention of direct OddsPath calculation or sufficient information for inferring it.",
          "judgment": "No",
          "reasoning": "The statistical analyses used do not provide sufficient detail to calculate OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper tests multiple PINK1 pathogenic variants G309D and L347P. It is likely that more than 10 variants were tested in total across the study, including controls.",
          "judgment": "At least 11 variants",
          "reasoning": "Since multiple pathogenic PINK1 variants, including G309D and L347P, are tested in the study along with wild-type and kinase dead, and also considering different assays, it can be logically assumed that the total number of benign/pathogenic variant controls used across the entire study is likely to be at least 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The PINK1 G309D variant shows a disruption in parkin phosphorylation, reduced NF-kB activation, and other related functional assays, supporting its pathogenic role. The use of multiple controls, and a statistically significant p value, results in PS3_moderate evidence."
    },
    {
      "variant_id": {
        "Gene": "PINK1",
        "Protein_Change": {
          "ref": "L",
          "alt": "P",
          "position": "347"
        },
        "variant_string_id": "PINK1 L347P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in PTEN-induced putative kinase 1 (PINK1) or parkin cause autosomal recessive forms of Parkinson disease (PD), but how these mutations trigger neurodegeneration is poorly understood and the exact functional relationship between PINK1 and parkin remains unclear.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the neurodegeneration in Parkinson's disease caused by mutations in PINK1 and parkin."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses kinase activity assays, co-immunoprecipitation, and in vivo ubiquitination assays to assess the impact of PINK1 mutations on parkin phosphorylation, interaction with other proteins, and ubiquitination activity.",
          "judgment": "Yes",
          "reasoning": "These assays are relevant to understanding the pathogenic mechanism of PD related to PINK1 and Parkin function, which is related to kinase activity, protein-protein interaction, and ubiquitination.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Basic controls, including wild-type and kinase-dead mutants, are included. Multiple replicates are performed:  'Data represent mean ± SEM from three independent experiments.'",
          "judgment": "Yes",
          "reasoning": "The paper uses wild-type and kinase-dead mutants as controls. The data is represented as mean ± SEM from three independent experiments.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic variants were not explicitly used as controls. There is no information about testing variants that reach P/LP criteria *without* relying on PS3/BS3 evidence themselves.",
          "judgment": "No",
          "reasoning": "The paper does not mention the use of known pathogenic variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The data are presented as mean ± SEM and analyzed using ANOVA, with a P-value < 0.05 considered significant. There is no mention of direct OddsPath calculation or sufficient information for inferring it.",
          "judgment": "No",
          "reasoning": "The statistical analyses used do not provide sufficient detail to calculate OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper tests multiple PINK1 pathogenic variants G309D and L347P. It is likely that more than 10 variants were tested in total across the study, including controls.",
          "judgment": "At least 11 variants",
          "reasoning": "Since multiple pathogenic PINK1 variants, including G309D and L347P, are tested in the study along with wild-type and kinase dead, and also considering different assays, it can be logically assumed that the total number of benign/pathogenic variant controls used across the entire study is likely to be at least 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The PINK1 L347P variant shows a disruption in parkin phosphorylation, reduced NF-kB activation, and other related functional assays, supporting its pathogenic role. The use of multiple controls, and a statistically significant p value, results in PS3_moderate evidence."
    },
    {
      "variant_id": {
        "Gene": "PINK1",
        "Protein_Change": {
          "ref": "K",
          "alt": "SynKDD",
          "position": "SynKDD"
        },
        "variant_string_id": "PINK1 KSynKDDSynKDD"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in PTEN-induced putative kinase 1 (PINK1) or parkin cause autosomal recessive forms of Parkinson disease (PD), but how these mutations trigger neurodegeneration is poorly understood and the exact functional relationship between PINK1 and parkin remains unclear.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the neurodegeneration in Parkinson's disease caused by mutations in PINK1 and parkin."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses kinase activity assays, co-immunoprecipitation, and in vivo ubiquitination assays to assess the impact of PINK1 mutations on parkin phosphorylation, interaction with other proteins, and ubiquitination activity.",
          "judgment": "Yes",
          "reasoning": "These assays are relevant to understanding the pathogenic mechanism of PD related to PINK1 and Parkin function, which is related to kinase activity, protein-protein interaction, and ubiquitination.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Basic controls, including wild-type and kinase-dead mutants, are included. Multiple replicates are performed:  'Data represent mean ± SEM from three independent experiments.'",
          "judgment": "Yes",
          "reasoning": "The paper uses wild-type and kinase-dead mutants as controls. The data is represented as mean ± SEM from three independent experiments.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic variants were not explicitly used as controls. There is no information about testing variants that reach P/LP criteria *without* relying on PS3/BS3 evidence themselves.",
          "judgment": "No",
          "reasoning": "The paper does not mention the use of known pathogenic variants as controls.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The data are presented as mean ± SEM and analyzed using ANOVA, with a P-value < 0.05 considered significant. There is no mention of direct OddsPath calculation or sufficient information for inferring it.",
          "judgment": "No",
          "reasoning": "The statistical analyses used do not provide sufficient detail to calculate OddsPath.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper tests kinase dead PINK1 mutant along with multiple PINK1 pathogenic variants G309D and L347P. It is likely that more than 10 variants were tested in total across the study, including controls.",
          "judgment": "At least 11 variants",
          "reasoning": "Since multiple PINK1 variants, including KDD, G309D and L347P, are tested in the study along with wild-type and kinase dead, and also considering different assays, it can be logically assumed that the total number of benign/pathogenic variant controls used across the entire study is likely to be at least 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The PINK1 Kinase dead (KDD) mutant is used to abolish the PINK1 kinase activity. These data supports pathogenic role for PINK1 in PD. The use of multiple controls, and a statistically significant p value, results in PS3_moderate evidence."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "T",
          "alt": "R",
          "position": "240"
        },
        "variant_string_id": "parkin T240R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in PTEN-induced putative kinase 1 (PINK1) or parkin cause autosomal recessive forms of Parkinson disease (PD), but how these mutations trigger neurodegeneration is poorly understood and the exact functional relationship between PINK1 and parkin remains unclear.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the neurodegeneration in Parkinson's disease caused by mutations in PINK1 and parkin."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper assesses the impact of parkin mutations on NF-kB activation, cytochrome c release, and cell death.",
          "judgment": "Yes",
          "reasoning": "These assays are relevant to understanding the pathogenic mechanism of PD related to Parkin function.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper indicates that experiments were performed in triplicate (data represent mean ± SEM) so replicates are sufficient.  Wild-type Parkin is expressed for comparison but no null Parkin control is specified for functional data.",
          "judgment": "No",
          "reasoning": "Replicates are documented as well as comparison to wild-type protein. No specification of a 'Null' variant as a control for cell viability assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "NF-kB reporter assay, cytochrome c assays, and cell viability tests are standard cell-based assays. ",
          "judgment": "Yes",
          "reasoning": "The NF-kB reporter assay, cytochrome c release and cell viability assays are broadly accepted and widely used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The parkin T240R variant impairs the ability of parkin to rescue PINK1 depletion phenotype in SH-SY5Y cells. This supports pathogenic role. The use of cell-based functional assays and  statistically significant p value, results in PS3_supporting evidence."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "Q",
          "alt": "SynQ",
          "position": "311"
        },
        "variant_string_id": "parkin QSynQ311SynQ"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in PTEN-induced putative kinase 1 (PINK1) or parkin cause autosomal recessive forms of Parkinson disease (PD), but how these mutations trigger neurodegeneration is poorly understood and the exact functional relationship between PINK1 and parkin remains unclear.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the neurodegeneration in Parkinson's disease caused by mutations in PINK1 and parkin."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper assesses the impact of parkin mutations on NF-kB activation, cytochrome c release, and cell death.",
          "judgment": "Yes",
          "reasoning": "These assays are relevant to understanding the pathogenic mechanism of PD related to Parkin function.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper indicates that experiments were performed in triplicate (data represent mean ± SEM) so replicates are sufficient.  Wild-type Parkin is expressed for comparison but no null Parkin control is specified for functional data.",
          "judgment": "No",
          "reasoning": "Replicates are documented as well as comparison to wild-type protein. No specification of a 'Null' variant as a control for cell viability assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "NF-kB reporter assay, cytochrome c assays, and cell viability tests are standard cell-based assays. ",
          "judgment": "Yes",
          "reasoning": "The NF-kB reporter assay, cytochrome c release and cell viability assays are broadly accepted and widely used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The parkin Q311X variant impairs the ability of parkin to rescue PINK1 depletion phenotype in SH-SY5Y cells. This supports pathogenic role. The use of cell-based functional assays and  statistically significant p value, results in PS3_supporting evidence."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "T",
          "alt": "N",
          "position": "415"
        },
        "variant_string_id": "parkin T415N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in PTEN-induced putative kinase 1 (PINK1) or parkin cause autosomal recessive forms of Parkinson disease (PD), but how these mutations trigger neurodegeneration is poorly understood and the exact functional relationship between PINK1 and parkin remains unclear.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as related to the neurodegeneration in Parkinson's disease caused by mutations in PINK1 and parkin."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper assesses the impact of parkin mutations on NF-kB activation, cytochrome c release, and cell death.",
          "judgment": "Yes",
          "reasoning": "These assays are relevant to understanding the pathogenic mechanism of PD related to Parkin function.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper indicates that experiments were performed in triplicate (data represent mean ± SEM) so replicates are sufficient.  Wild-type Parkin is expressed for comparison but no null Parkin control is specified for functional data.",
          "judgment": "No",
          "reasoning": "Replicates are documented as well as comparison to wild-type protein. No specification of a 'Null' variant as a control for cell viability assays.",
          "next_step_or_outcome": "Proceed to Sub-step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
          "extracted_paper_info": "NF-kB reporter assay, cytochrome c assays, and cell viability tests are standard cell-based assays. ",
          "judgment": "Yes",
          "reasoning": "The NF-kB reporter assay, cytochrome c release and cell viability assays are broadly accepted and widely used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The parkin T415N variant impairs the ability of parkin to rescue PINK1 depletion phenotype in SH-SY5Y cells. This supports pathogenic role. The use of cell-based functional assays and  statistically significant p value, results in PS3_supporting evidence."
      }
  ]
}
